• 不 限
  • 期刊论文
  • 硕博论文
  • 会议论文
  • 报 纸
  • 英文论文
  2. 您的位置
  3. 首页
  4. 会议论文
  5. Artesunate exhibits synergistic anti-cancer effects with cisplatin on lung cancer A549 cells by inhi

Artesunate exhibits synergistic anti-cancer effects with cisplatin on lung cancer A549 cells by inhi

来源 :2019中国肿瘤学大会 | 被引量 : 0次 | 上传用户：aramis_Rose
【摘 要】
：
Objective Artesunate(ART)has been used extensively as anti-malarial drugs worldwide.Besids,it has also been reported to have anti-cancer activities.However,few studies have investigated the exact anti
【作 者】
：
Wen Li Qinghua Zhou 
【机 构】
：
West China Hospital,Sichuan University
【出 处】
：
2019中国肿瘤学大会
【发表日期】
：
2019年7期
【关键词】
：
Artesunate Cisplatin Lung cancer Synergistic Proliferation Apoptosis 
下载到本地 , 更方便阅读
下载此文 赞助VIP
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
　　Objective Artesunate(ART)has been used extensively as anti-malarial drugs worldwide.Besids,it has also been reported to have anti-cancer activities.However,few studies have investigated the exact anti-tumor and chemosensitization effects of ART on lung cancer cells.Herein,this study was designed to explore the anti-cancer effects of ART in combination with CIS on lung cancer cells in vitro and vivo,with an emphasis on the molecular mechanism.
其他文献
Sensitization of the efficiency of immunotherapy in HCC by polyIC-triggered CXCL10 secretion in live
Objective Nowadays,the immune checkpoint blockades(ICBs)have been widely used in various kinds of tumors and its also such a hot spot in the research area.
会议
Hepatocellular carcinomaImmune checkpoint blockadePolyinosinicpolycytidylic ac
WM130 preferentially inhibits hepatic cancer stem-like cells by suppressing AKT/GSK3β/β-catenin sign
会议
matrine derivativehepatocellular carcinomacancer stem-like cellsGSK3βAKT
Synergistic effect and Mechanism of E3330 Combination with Vemurafenib in the Treatment of Papillary
会议
BRAF MutationinhibitorvemurafenibE3330synergyPTC
BI2536联合Stattic通过MYC治疗胶质母细胞瘤的实验研究
目的 本研究旨在研究PLK1 抑制剂BI2536 联合STAT3 抑制剂Stattic 通过MYC 诱导胶质瘤细胞凋亡的分子机制，为靶向PLK1 联合STAT3 治疗胶质瘤提供科学依据。
会议
PLK1STAT3MYC胶质瘤
Apatinib inhibits cell proliferation and induces autophagy via the PI3K/Akt signaling pathway in hum
Objective Objective: PTC is the most common type of thyroid cancer and has a favorable prognosis.However,patients with metastatic radioiodine-refractory papillary thyroid carcinoma(PTC)have limited op
会议
Apatinibpapillary thyroid carcinomaapoptosisautophagy
Saracatinib抑制EGFRvⅢ阳性胶质瘤干细胞“干性”特征的实验研究
目的 EGFRvⅢ 是胶质母细胞瘤中最常见的突变，具有促进胶质母细胞瘤进展的多种活性。本研究旨在通过体内、外实验揭示SRC 家族激酶抑制剂Saracatinib 对EGFRvⅢ 阳性胶质瘤干细胞的抑制作用。
会议
EGFRvⅢSaracatinib胶质瘤干细胞SRC
PAK1小分子抑制剂AK963抑制人胃癌细胞增殖迁移及机制研究
目的 胃癌是我国最常见的恶性肿瘤,在我国其发病率和死亡率居各类肿瘤的首位,因此,寻找胃癌的治疗靶点是当前肿瘤研究领域的热点.P21 活化蛋白激酶1(p21-activated kinase 1,PAK1)作为I 类PAK 家族的代表,是进化上保守的丝氨酸/苏氨酸蛋白激酶,在肿瘤细胞信号转导过程中具有枢纽作用,因此已成为有效的肿瘤治疗靶点.但目前针对该靶点抑制剂的研究正处于起步阶段.
会议
P21活化激酶1抑制剂胃癌增殖迁移
Nek2B activates the wnt pathway and promotes triplenegative breast cancer chemotherapy-resistance by
Objective The molecular mechanism of chemotherapy-resistance in triple-negative breast cancer(TNBC)is unclear.Centrosomal kinase Nek2B is the only Nek2 isomer through the whole process of mitosis.Our
会议
β-cateninWnt signaling pathwayTriple-negative breast cancerChemotherapy resis
靶向vegf/vegfr2基因siRNA对小鼠B16F10移植瘤生长的影响
目的 血管内皮生长因子(vascular endothelial growth factor,VEGF)是目前已知的最重要的血管生成调节因子,VEGF 与其受体(vascular endothelial growth factor receptor,VEGFR)特异性结合,调节着血管及肿瘤血管的生成。本研究靶向vegf 及其受体vegfr2 基因 siRNA 对小鼠黑色素瘤细胞B16F10 移植瘤
会议
血管内皮生长因子血管内皮生长因子受体2RNA干扰B16F10移植瘤
Mifepristone Derivative FZU-00,003 Suppresses Triplenegative Breast Cancer Cell Growth partially via
Objective Triple-negative breast cancer(TNBC)is one of the most malignant breast cancers lacking targeted therapeutics currently due to the heterogeneity of the disease,the absence of well-defined mol
会议
FZU-00003KLF5breast cancerMIF derivatives